The rising costs of generic drugs have led to outcries. In a search for solutions, four hospital systems are proposing to make drugs on their own. Could their idea work?
L’expertise universitaire, l’exigence journalistique
Articles sur Drug prices
Affichage de 21 à 32 de 32 articles
Rather than being designed by chemists, this class of pharmaceuticals is produced by living cells. Here’s where they come from and how they work.
Drug prices in Australia are three times higher than in New Zealand. A key reason is the lack of transparency about taxpayer subsidies for Big Pharma and the companies’ own finances.
An independent expert provides his pick of the most notable drugs added to the PBS on May 1, 2017.
The Orphan Drug Act was enacted 34 years ago to encourage the development of drugs for rare diseases. Drug companies were guaranteed seven years of exclusivity. Then the rush was on to run up prices.
Australia is spending more than A$500 million a year too much for pharmaceuticals because of a little known loophole that allows drug companies to overcharge the government.
The rising cost of drugs is more worrisome to most Americans than problems with Obamacare. Could proposals in California and Ohio help?
Pharmaceutical companies aim to make a profit, but it took an industry insider to blow the whistle on some exorbitant drug costs the NHS was paying.
Clinton, who named drug companies among her enemies in this week’s debate, is pushing populist-inspired policies that could hamper the flow of new medicines.
Most of us would agree that cancer drugs should be listed on the PBS, no matter how dear. But our health system can’t afford all of them. How then are decisions about which drugs to subsidise made?
Over the next few weeks, the trade minister will be under intense pressure to renege on the government’s commitment to reject anything in the Trans Pacific Partnership that could undermine the PBS.
Hope, fear, and desperation, along with the unique characteristics of the cancer drug market, create a “perfect storm” that continues to drive up prices for cancer drugs.
Les contributeurs les plus fréquents
-
Joel Lexchin est un·e ami·e de La ConversationProfessor Emeritus of Health Policy and Management, York University, Canada
-
Research Fellow, Flinders University
-
Professor of Health Economics, Flinders University
-
Lecturer in Accounting & Management, Lancaster University
-
Associate Professor of Public Health, Texas A&M University
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Associate Professor of Markets, Public Policy and Law, Boston University
-
Adjunct professor, Department of Health Policy & Management, George Washington University
-
Associate Professor in Public Health, La Trobe University
-
Associate Professor in Health Economics, Flinders University
-
Associate Professor of the School of Pharmacy, University of Sydney
-
Professor of Philosophy, Binghamton University, State University of New York
-
Dean of the Sol Price School of Public Policy; Distinguished Professor of Pharmacy, Public Policy, and Economics, University of Southern California
-
Adjunct Associate Professor, School of Social and Political Sciences, University of Sydney
-
Macquarie University Research Fellow, Macquarie University
